Inhibition of *Leishmania major* PTR1 Gene Expression by Anti-sense in *Escherichia coli*

**F Kheirandish**, **M Bandehpour**, **A Haghighi**, **F Mahboudi**, **M Mohebali**, **B Kazemi**

1. Dept. of Parasitology and Mycology, School of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran
2. Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Biotechnology Department, School of Medicine, Shahid Beheshti University of Medical Sciences Tehran, Iran
4. Dept. of Parasitology and Mycology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5. Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
6. Dept. of Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

(Received 19 Nov 2011; accepted 12 Mar 2012)

**Introduction**

*Leishmania major* protozoa are the causative agent of human zoonotic cutaneous leishmaniasis. Studies have shown that the growth of protozoa related to Trypanosome family depends on (folate-pteridine) (1). Protozoa related to Trypanosome family including *Leishmania* synthesizes enzymes to escape from drug therapy. One of these enzymes is PTR1 (1-9). The enzymatic activity of PTR1 is similar to dihydrofolate reductase (DHFR) (10, 11). DHFR plays a role in activating the enzyme of thymidylate synthase (TS) that catalyzes the conversion of deoxyuridylate in to deoxythymidylate and another role of DHFR is the reduction of dihydrofolate (H2-folate) to tetrahydrofolate (H4-folate) (9); the recent product is co-factor of thymidylate synthase (9-11). Thus DHFR-TS has a major role in DNA synthesis, if it is inhibited, the result would be the death of parasite (1). Genesis drugs on metabolism in mediating cell proliferation are important affect; one

**Abstract**

**Background:** Protozoa related to Trypanosome family including *Leishmania*, synthesize enzymes to escape from drug therapy. One of them is PTR1 that its enzymatic activity is similar to dihydrofolate reductase (DHFR). Dihydrofolate reductase - thymidylate synthase has a major role in DNA synthesis, if it is inhibited, the result would be the death of parasite. Since PTR1 activity is similar to DHFR, causes the decrease of inhibition effect of drug. The aim of this study was inhibition of Iranian *L. major* PTR1 expression with mRNA antisense in prokaryotic system as an approach to appear of the drugs therapeutic effects more.

**Methods:** PTR1 gene was ligated to pACYCDuet-1 and pcDNA3 plasmids as sense and antisense plasmids, respectively. Simultaneously transfer of sense and antisense plasmids was done in *E. coli* strain M15. SDS-PAGE and western blot analysis were carried out to analyze the expression.

**Results:** Sense and antisense plasmids were prepared and confirmed by restriction analysis and PCR then simultaneously transfer of them was done. SDS-PAGE and western blot analysis showed PTR1 gene was inhibited by mRNA antisense in bacterial cells.

**Conclusion:** Expression of PTR1 gene in sense plasmid was inhibited successfully by antisense plasmid.

**Keywords:** PTR1, *Leishmania major*, Antisense plasmid, Dihydrofolate reductase, Expression

*Corresponding Author: Tel: +9821 22439956, E-mail address: kazemi@sbmu.ac.ir*

Available at: [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)
of the mechanisms of drug is inhibition of DHFR-TS (1). Since PTR1 activity is similar to DHFR causes the decrease of inhibition effect of drug (10, 11). On the other hand, PTR1 causes synthesis and reduction of pteridine that increases the resistance of parasite against oxidative stress-related drug or reactions of the host (1, 2, 12). Because of production of enzymes by *Leishmania* including PTR1, the drug efficacy has been decreased and no response to treatment is observed, therefore, it is suggested that in addition of prescription of anti-parasite drugs, these enzymes inhibit in such way that the therapeutic effects of drugs appear more (1).

The aim of this study was inhibition of Iranian *L. major* PTR1 expression with antisense RNA in prokaryotic system.

**Materials And Methods**

**Sense and antisense plasmids construction**

In order to transfer of sense and antisense plasmids in one bacterial cell, two different plasmids with two different origins of replication, and two different antibiotic resistance genes were needed. The position of restriction enzyme cut sites used on the plasmids was in two different directions. BamH I and Hind III were considered on the sense plasmid, as the expression, PTR I protein was produced. In addition, BamH I and KpnI were considered on antisense plasmid, in this case gene order placement is in the reverse mode.

For this purpose, plasmids pACYCDuet-1 and pcDNA3 were used for the sense and antisense plasmids, respectively. Plasmid pQE–ptr that has been described previously (13), was digested by Hind III and BamH I to release the PTR1 gene. The fragment was cloned into Hind III and BamH I digested pACYCDuet-1. This vector was transformed in *E. coli* strain M15 then extracted and confirmed by restriction analysis and PCR.

For preparing of antisense plasmid, pQE–ptr (13) was digested by kpn I and BamH I to release the PTR1 gene. The fragment was cloned into pcDNA3, which was lineared by kpn I and BamH1. Recombinant plasmid was transformed in *E. coli* strain M15.

Recombinant plasmids were extracted and confirmed by restriction analysis and PCR.

**Simultaneously transformation of sense and antisense plasmid in one bacterial cell**

The *E. coli* strain M15 was transformed with pACYCDuet–ptr and selected on Luria Bertani agar containing 30 µg/ml chloramphenicol. These cells were transformed again with pcDNA–Rptr and selected on Luria Bertani agar containing 50 µg/ml ampicillin and 30 µg/ml chloramphenicol. Transformation of pACYCDuet–ptr and pcDNA–Rptr in the *E. coli* strain M15 was done separately as control and selected on Luria Bertani agar containing selective antibiotics. *E. coli* strain M15 was susceptible to used selective antibiotics.

**Gene expression**

Gene expression was done as previously described (13, 14) by a little modification. Briefly, the transformant *E. coli* strain M15 with both of sense and antisense plasmids was inoculated into 3 ml culture tube containing X medium (1.2% bacato trypton, 2.4% yeast extract, 0.04% glycerol, 1% M9 salts) (M9 salt containing 6.4% Na2HPO4–7H2O, 1.5% KH2PO4, 0.025% NaCl, 0.05% NH4Cl) and allowed to grow at 37°C in a shaker incubator at 200 rpm overnight. The day after, it was inoculated in to 50 ml flask and allowed at 37°C in a shaker incubator at 200 rpm. The culture in the logaritmic phase (at OD 600 = 0.6) was inducted with 0.8mM ispropyl-B-D-thiogalactopyranosid (IPTG) for 5 hours. After induction, cells were withdrawn and analyzed by 10% SDS–PAGE (15). Induced and uninduced the transformant bacterial cells with pcDNA-Rptr and pACYC Duet–ptr were analyzed in parallel.

**Western blot analysis**

For immunoblotting, proteins resolved by SDS-PAGE were electrophoretically transferred onto nitrocellulose membrane (13). Then UV cross linker was used for protein fixation. The membrane was blocked with 3% BSA (Bovine Serum
Albumin) at room temperature and washed twice with TBS (Tris-Buffered Saline) after 1 h. After that incubated for 1 h at 37 °C with the rabbit anti-PTR1 antiserum at a 1:1000 dilution as the primary antibody. The membrane was washed three times with TBS-T (TBS-TWEEN 20) and incubated for 1 h at 37 °C with the goat anti-rabbit IgG HRP conjugate solution at a 1:5000 dilution as secondary antibody (13, 16). Antibody binding was visualized using calorimetry with diaminobenzidine (DAB) and H2O2.

**Results**

**Preparation of sense and antisense plasmids:**
Plasmid pQE-PTR1 that was the source of the *L. major* PTR1 gene (13) was digested with restriction enzymes and released the PTR1 gene. The PTR1 gene was ligated to pACYCDuet-1 and pcDNA3 then confirmed by restriction analysis and PCR (Fig. 1, Fig. 2, Fig. 3, Fig. 4) and named pACYCDuet–ptr and pcDNA–Rptr, respectively.

**Fig. 1:** Electrophoresis of PCR product on 1% agarose gel
Lane 1: The 1202 bp as PCR product of pACYCDuet-ptr
Lane 2: The 369 bp as PCR product of pACYCDuet-1
Lane 3: 100 bp DNA ladder marker

**Fig. 2:** 1.5% Agarose gel electrophoresis
Lane 1: Digested pACYCDuet-ptr by BamH I and Hind III
Lane 2: 100 bp DNA ladder marker

**Fig. 3:** Electrophoresis of PCR product on 1% agarose gel
Lane 1: 100 bp DNA ladder marker
Lane 2: The 808 bp as PCR product of pcDNA-Rptr

Available at: http://ijph.tums.ac.ir
Fig. 4: 1.5% Agarose gel electrophoresis
Lane 1: 100 bp DNA ladder marker
Lane 2: Digested pcDNA-Rptr by BamH I and KpnI

The results of the simultaneously transfer of sense and antisense plasmids:
Plate from simultaneously transfer of pACYC-Duet-ptr and pcDNA-Rptr plasmids contained colonies. Since the plate contained selective antibiotics (ampicillin, chloramphenicol) in every plasmid, the presence of colonies in such plate indicated the simultaneous presence of both plasmids in one bacterial cell.

Inhibition of gene expression in the sense plasmid by antisense plasmid:
SDS-PAGE and Western blot analysis:
SDS-PAGE on lysate collected transformed bacteria with both of pACYC-Duet-ptr and pcDNA-Rptr plasmids before and 5 hours after induction was performed. Induced bacteria containing pACYC-Duet-ptr and induced bacteria containing pcDNA-Rptr also were analyzed in parallel. If the cloned PTR1 gene expressed in sense plasmid (pACYC-Duet-ptr), the protein with molecular weight of about 30 kDa was expected. While the lysate bacteria containing both sense and antisense plasmids also lysate bacteria containing antisense plasmid, after induction any trace of protein was observed in this range that this results indicate the inhibition of gene expression in sense plasmid by antisense plasmid (Fig. 5). Final confirmation was performed with western blotting (Fig. 6).

Fig. 5: 10% SDS-PAGE of bacterial lysate
Lane 1: Lysate of M15 cell containing pcDNA-Rptr collected 5hrs after induction
Lane 2: Lysate of M15 cell containing pACYC-Duet-ptr collected 5hrs after induction
Lane 3: Lysate of M15 cell containing pACYC-Duet-ptr and pcDNA-Rptr collected 5hrs after induction
Lane 4: Lysate of M15 cell containing pcDNA-Rptr collected before induction
Lane 5: Lysate of M15 cell containing pACYC-Duet-ptr collected before induction
Lane 6: Lysate of M15 cell containing pACYC-Duet-ptr and pcDNA-Rptr collected before induction

Fig. 6: Western blot analysis
Lane 1: Lysate of M15 cell containing pcDNA-Rptr collected 5hrs after induction
Lane 2: Lysate of M15 cell containing pACYC-Duet-ptr collected 5hrs after induction
Lane 3: Lysate of M15 cell containing pACYC-Duet-ptr and pcDNA-Rptr collected 5hrs after induction
Lane 4: Lysate of M15 cell containing pcDNA-Rptr collected before induction
Lane 5: Lysate of M15 cell containing pACYC-Duet-ptr collected before induction
Lane 6: Lysate of M15 cell containing pACYC-Duet-ptr and pcDNA-Rptr collected before induction

Discussion

Leishmaniasis is one of the parasitic diseases in most parts of the world. Out of the 30 provinces of Iran in the 15 provinces, leishmaniasis is endemic (17, 18). In addition to reports in the world about Leishmania which is resistant to drugs (19, 20) in Iran 10 to 15 percent of people infected with cutaneous leishmaniasis have been treated with Glucantime; they have no response to treatment that one of the reasons is drug-resistant parasites (21). Studies concerning methods of treatment of cutaneous leishmaniasis was conducted but none has been quite favorable (22, 23). According to the mentioned subjects, there is no completely effective drug therapy for treatment of cutaneous leishmaniasis and some failures are seen in the treatment that the lack of proper medical response is due to drug resistance, which needs more research. As was mentioned DHFR in parasitic DNA synthesis has an important role and inhibit this enzyme is causing the death. Methotrexate, one of anti-metabolite drugs, is an antagonist for folic acid, which competitively will inhibit DHFR, and its result is the death of parasite (24-25). PTR1 enzyme of Leishmania with similar enzymatic activity to DHFR reduced parasite susceptibility to anti-metabolite drugs such as Methotrexate (26) and was shown that deletion of PTR1 gene in Leishmania, which are treated with Methotrexate causes the death of parasite (27).

To inhibit gene expression, different several ways have been reported such as, oligodeoxy nucleotides (ODNs) (28), mRNA antisense (29) and small interfering RNA (siRNA) molecules (30). The purpose of this study is to identify inhibiting power of sense plasmid by complete antisense plasmid in vitro. After preparing the sense and antisense plasmids, since origin of replication of both plasmids was different and were in compatibility group, transformation of both in a bacterial cell was done successfully and then expression was induced. The results of SDS-PAGE and western blot analysis showed inhibition of sense plasmid by antisense plasmid. In addition, it was shown that the inhibition occurs in the cytosol, as was reported by Dumas et al (31).

In conclusion, expression of PTR1 gene in sense plasmid was inhibited successfully by antisense plasmid. Because the mRNA antisense can be used in gene therapy, the results of this study showed that this method could be successful.

Ethical considerations

Ethical issues (Including plagiarism, Informed Consent, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc) have been completely observed by the authors.

Acknowledgements

This study was supported by the EMGEN (Eastern Mediterranean Health Genomics & Biotechnology Network) through project number 20091 and carried out in Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, and the authors would like to thank the personal and the director of the center. The authors declare that there is no conflict of interests.

References

1. Nare B, Luba J, Hardy LW, Beverley SM (1997). New approaches to Leishmania chemotherapy: pteridine reductase 1 (PTR1) as
a target and modulator of antifolate sensitivity. *Parasitol*, 114 Suppl: S101-S110.

2. Bello AR, Nare B, Freedman D, Hardy L, Beverley SM (1994). PTRI: a reductase mediating salvage of oxidized pteridines and methotrexate resistance in the protozoan parasite *Leishmania major*. *PNAS USA*, 91 (24): 11442-11446.

3. Ellenberger TE, Beverley SM (1989). Multiple drug resistance and conservative amplification of the H region in *Leishmania major*. *J Biol Chem*, 264 (25): 15094-15103.

4. Papadopoulou B, Roy G, Ouellette M (1992). A novel antifolate resistance gene on the amplified H circle of *Leishmania*. *EMBO J*, 11 (910): 3601-3608.

5. Arrebola R, Olmo A, Reche P Garvey EP, Santi DV, Ruiz-oerez LM, Gonzalez-Pacanowska D (1994). Isolation and characterization of a mutant dihydrofolate reductase–thymidylate synthase from methotrexate– resistant *Leishmania* cells. *J Biol Chem*, 269 (14): 10590-10596.

6. Beck JT, Ullman B (1991). Biopterin conversion to reduced folates by *Leishmania donovani* promastigotes. *Mol Biochem Parasitol*, 49 (1): 21-28.

7. Govrley DG, Luba J, Hardy IW, Beverley SM, Hunter WN (1999). Crystallization of recombinant *Leishmania major* pteridine reductase 1 (PTRI). *Acta Cryst D Biol Crystallogr*, 55 (Pt 9): 1608–1610.

8. Luba J, Nare B, Liang PH, Anderson KS, Beverley SM, Hardy IW (1998). *Leishmania major* pteridine reductase 1 belongs to the short chain dehydrogenase family: Stereochemical and kinetic evidence. *Biochemistry*, 37 (12): 4093-4104.

9. Nare B, Hardy L, Beverley SM (1997). The roles of pteridine reductase 1 (PTRI) and dihydrofolate reductase – thymidylate synthase (DHFR-TS) in pteridine metabolism in the protozoan parasite *Leishmania major*. *J Biol Chem*, 272 (21): 13883-13891.

10. Grogl M, Thomason TN, Franke ED (1992). Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease. *Am J Trop Med Hyg*, 47 (1): 117-126.

11. Cunningham ML, Beverley SM (2001). Pteridine salvage throughout the leishmania infectious cycle: implications for antifolate chemotherapy. *Mol Biochem Parasitol*, 113 (2): 199-213.

12. Nichol CA, Smith GK, Dutch DS (1985). Biosynthesis and metabolism of tetrahydrobiopterin and molybdopterin. *Annu Rev Biochem*, 54 (1): 729-764.

13. F Kheirandish, M Bandehpour, A Haghhighi, F Mahboudi, M Mohebali, N Mosaffa, B Kazemi (2008). Molecular Cloning and Expression of Iranian *Leishmania major* Pteridine Reductase 1. *Iranian J Parasitol*, 3 (2): 1-9.

14. Appelbaum ER, Shatzman AR (1999). Protein expression, a practical approach. Ed, SJ Higgins, BD Hames. Pp. 169-200.

15. Sambrook J, Russell DW (2001). Molecular cloning . A laboratory manual, Cold spring harbor laboratory press. pp. 4-14.

16. Kumar P, Kothari H, Singh N (2004). Overexpression in *Escherichia coli* and purification of pteridine reductase (PTRI) from a clinical isolate of *Leishmania donovani*. *Protein Expr Purif*, 38 (2): 228-36.

17. Mohebali M, Javadian E, Yaghoobi-Ershadi MR, Akhavan AA, Hajaran H, Abaei MR (2004). Characterization of *Leishmania* infection in rodents from endemic areas of the Islamic Republic of Iran. *East Mediterr Health J*, 10 (4-5): 591-599.

18. Mohebali M, Edrissian GH, Namd A, Hajaran H, Akhoundi B, Hooshmand S, Sanati AA, Moshfe AA, Charhedar S, Fakhour M (2006). Application of direct agglutination test (DAT) for the diagnosis and seroepidemiological studies of visceral leishmaniasis in the Islamic Republic of Iran. *Iranian J Parasitol*, 1 (1): 15-25.

19. Ouellette M (2001). Biochemical and molecular mechanisms of drug resistance in parasites. *Trop Med Int Health*, 6 (11): 874–876.

20. Sunder S (2001). Drug resistance in Indian visceral leishmaniasis. *Trop Med Int Health*, 6 (11): 849- 855.

21. Hadighi R, Boucher P, Khamesipour A, Meammar AR, Roy G, Ouellette M, Mohebali M (2007). Glucantime-resistant *Leishmania tropica* isolated from Iranian patients with
cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. *Parasitol Res*, 101 (5): 1319-1322.

22. Asilian A, Jalayer T, Whitworth JAG, Ghasemi RL, Niforooszhadeh M, Olliaro P (1995). A randomized, placebo, controlled trial of a two-week regimen of aminacidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. *Am J Trop Med Hyg*, 53 (6): 648-651.

23. Asilian A, Jalayer T, Niforooszhadeh M, Ghasemi RL, Peto R, Wayling S, Olliaro P, Modabber F (2003). Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double – blind, randomized trial in the Islamic Republic of Iran. *Bulletin WHO*, 81 (5): 353-359.

24. Coderre AJ, Beverley MS, Schinmke R, Santi DV (1983). Overproduction of a bifunctional thymidylate synthetase – dihydrofolate reductase and DNA amplification in methotrexate-resistant *Leishmania tropica*. *Proc Natl Acad Sci USA*, 80 (8): 2132-2136.

25. Bello RA, Nara B, Freedman D, Hardy L, Beverley SM (1994). PTRI: A reductase mediating salvage of oxidized pteridines and methotrexate resistance in the protozoan parasite *Leishmania major*. *Proc Natl Acad Sci USA*, 91 (24): 11442-11446.

26. Nare B, Hardy L, Beverley SM (1997). The roles of pteridine reductase 1 and dihydrofolate reductase–thymidylate synthase in pteridine metabolism in the protozoan parasite *Leishmania major*. *J Biol Chem*, 272 (21): 13883-13891.

27. Cunningham ML, Beverley SM (2001). Pteridine salvage throughout the *Leishmania* infectious cycle: implications for antifolate chemotherapy. *Mol Biochem Parasitol*, 113 (2): 199-213.

28. Wagner RW (2002). Gene inhibition using antisense oligodeoxynucleotides. *Nature*, 372 (6504): 33-335.

29. Mundodi V, Kucknoor AS, Gedamu L (2005). Role of *Leishmania (Leishmania) chagasi* amastigote cysteine protease in intracellular parasite survival: studies by gene disruption and antisense mRNA inhibition. *BMC Mol Biol*, 6 (1):3.

30. Zhang W, Chen X, Qui F (2003). An antisense plasmid targeting surviving expression induces apoptosis and sensitizes hepatocarcinoma cells to chemotherapy. *J Huazhong Univ Sci Technology Med Sci*, 23 (4): 387-391.

31. Dumas C, Chow C, Muller M, Papadopoulou B (2006). A novel class of developmentally regulated noncoding RNAs in *Leishmania*. *Eukaryot Cell*, 5 (12): 2033-2046.

Available at: http://ijph.tums.ac.ir